Hayley Virgil

Senior Editor, OncLive®
Hayley Virgil heads OncLive's feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

Articles

Drive-By Flu-FIT Program May Address CRC Screening Decline in Diverse Communities Amidst COVID-19 Crisis

February 3rd 2021

February 3, 2021 - The Drive-By Flu-Fecal Immunochemical Test program not only provides safe and socially distanced colorectal cancer screening opportunities during the coronavirus disease 2019 pandemic, but also may help to address screening declines in diverse communities.

Low-Dose Chest CT Reduces Lung Cancer Mortality, but Barriers Remain

February 3rd 2021

Florian Fintelmann, MD, discusses lung cancer screening with low-dose chest CT, barriers to testing, and the potential expansion of USPSTF lung cancer screening guidelines.

ASCO Names Molecular Profiling in GI Cancers as Advance of the Year

February 2nd 2021

February 2, 2021 - ASCO has chosen molecular profiling driving progress in gastointestinal cancers as its Advance of the Year.

HRQoL Maintained With Adjuvant Osimertinib in EGFR+ NSCLC

January 30th 2021

January 29, 2021 - Health-related quality of life was maintained for patients with EGFR-positive non–small cell lung cancer who received treatment with adjuvant osimertinib versus placebo, with no clinically meaningful differences noted between study arms.

Osimertinib/Savolitinib Combo May Overcome MET Resistance in EGFR+, MET-Amplified NSCLC

January 28th 2021

January 28, 2021 - The combination of osimertinib and savolitinib may be able to overcome MET resistance in patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer, including those who have previously progressed on a prior EGFR TKI.

Perioperative Chemotherapy Fails to Show OS Benefit in Resectable PDAC

January 27th 2021

January 27, 2021 - Perioperative chemotherapy did not improve overall survival in patients with resectable pancreatic ductal adenocarcinoma when compared with historical data from adjuvant trials.

Hurvitz Highlights Key Developments Made in Metastatic HER2+ Breast Cancer Paradigm

January 23rd 2021

Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer.

Deciding Between Adjuvant Targeted Therapy and Immunotherapy in BRAF+ Melanoma

January 22nd 2021

Reinhard Dummer, MD, shares his approach for selecting between targeted approaches and immunotherapy agents in the adjuvant treatment of patients with melanoma.

Determining How to Incorporate MRD Into Care Decisions for Myeloma

January 22nd 2021

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

Atezolizumab/Bevacizumab Is Favored for Further Study in HCC

January 22nd 2021

Joseph Kim, MD, discusses the multidisciplinary management of patients with HCC.

Mean Daily Step Count While Receiving SM-88 Correlates With Patient-Reported QoL in Metastatic Pancreatic Cancer

January 16th 2021

January 16, 2021 - Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer.

Liposomal Irinotecan Plus 5-FU Shows Real-World OS Benefit in Metastatic PDAC

January 15th 2021

January 15, 2021 - One-year overall survival was found increased the longer that patients with metastatic pancreatic ductal adenocarcinoma remained on treatment with liposomal irinotecan plus 5-fluorouracil/leucovorin.

Addition of HIPEC to Cytoreductive Surgery in CRC Peritoneal Carcinomatosis Warrants Further Investigation

January 13th 2021

Prakash Pandalai, MD, discusses the role of HIPEC in CRC peritoneal carcinomatosis and data from the PRODIGE 7 and PROPHYLOCHIP-PRODIGE 15 trials.

BET Inhibitor CC-90010 Shows Activity in Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma

January 7th 2021

January 7, 2021 - The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Less Tumor Texture Variability From Baseline May Be Linked With Better Outcomes in PDAC

January 7th 2021

January 7, 2021 - Patients with pancreatic ductal adenocarcinoma who were treated with a 920 mg dose of SM-88 were less likely to experience a change in tumor texture and were found to have more favorable outcomes, according to results from a phase 2 dose-escalation trial.

Vemurafenib Plus Cetuximab/Irinotecan Improves PFS in BRAF-Mutant Metastatic CRC

January 6th 2021

January 6th, 2021 - The addition of vemurafenib to irinotecan and cetuximab led to a significant improvement in progression-free survival versus irinotecan and cetuximab alone in patients with BRAF V600E–mutated metastatic colorectal cancer.

Manochakian Breaks Down Barriers to Genetic Testing in Lung Cancer

January 4th 2021

Rami Manochakian, MD, underscores the importance of looking for actionable alterations in lung cancer, barriers to genetic testing, and what is needed to overcome them.

Practice-Changing Trials Pave the Way for Novel Approaches in Metastatic Prostate Cancer

December 31st 2020

Joseph Kim, MD, discusses pivotal trials in metastatic prostate cancer, the rise of PARP inhibitors and novel combinations under investigation, and the promise of relugolix.

Mian Makes Sense of Multidisciplinary Bladder Preservation Approaches

December 31st 2020

Omar Mian, MD, PhD, discusses selective bladder preservation in patients with muscle-invasive bladder cancer, biomarkers of response, and the utilization of hypofractionated radiation vs traditional approaches in this population.

SAR439859 Achieves On-Target Activity in Metastatic ER+ Breast Cancer

December 28th 2020

December 28, 2020 - The investigational selective estrogen receptor degrader SAR439859 elicited clinical, on-target activity in patients with heavily pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer, even in the presence of multiple resistance mechanisms.